| Project/Area Number |
06670646
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
INUZUKA Takashi Niigata Univ. Medical school hospital. Assistant prof., 医学部・附属病院, 講師 (50184734)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAKANO Ryoichi Niigata Univ. Medical school hospital. Instructor, 医学部・附属病院, 助手 (00262444)
|
|---|
| Project Period (FY) |
1994 – 1995
|
| Project Status |
Completed (Fiscal Year 1995)
|
| Budget Amount *help |
¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 1995: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1994: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Keywords | anti-neural antibody / neuronal cell death / paraneoplastic neurological syndrome / limbic encephalopathy / survey for malingnancy / subacute cerebellar degeneration / subacute sensory neuropathy / 辺縁脳炎 |
|---|
| Research Abstract |
Paraneoplasitic neurological syndrome is the remote effects of cancer on the nervous system which is the least common of the nonmetastatic complication of cancer. Present evidence suggests that some patients with paraneoplastic syndromes harbor autoantibodies in the serum and CSF that react with neuronal elements as well as with tumors.
We isolated a cDNA clones "CZF" and "HuV" from a human brain library by immunoscreening using patients' sera and characterized them. We found that the clone "CZF" associated with paraneoplastic cerebellar degeneration (PCD) had zinc finger motives and the clone "HuV" associated with paraneoplastic sensory neuropathy had DNA binding sites and CAG triple repeats. These clones may affect transcription which is important to maintain neuronal cells. We made each recombinant partial protein, which was reacted by wech patient's serum, and produced antibody against each. Whole length cDNA cloning of "CZF" and "HuV" is still underway. We examined the effects of IgG from these and patient with anti-Hu antibody on cultured neuroblastoma cell line and found little effects in normal condition.
We produced recombinant partial HuD protein, and established immunoblot and ELISA systems for detection of anti-Hu antibody in the serum and CSF of patients. These systems were useful for screening of cancer, especially of small cell lung cancer, and monitoring the effects of chemotherapy or recurrence of cancer.
|
